From Wikipedia, the free encyclopedia
  (Redirected from 5-F-AMT)
Jump to: navigation, search
Systematic (IUPAC) name
Clinical data
Legal status
CAS number 712-08-3 N
ATC code ?
PubChem CID 12834
ChemSpider 12304 YesY
Chemical data
Formula C11H13FN2 
Mol. mass 192.233 g/mol
 N (what is this?)  (verify)

5-Fluoro-α-methyltryptamine (5-Fluoro-αMT or PAL-544),[1] is a tryptamine derivative. It is similar in structure to psychedelic tryptamines such as αMT and 5-MeO-αMT.

5-Fluoro-αMT has been found to act as a potent and selective MAO-A inhibitor,[2][3] and also as a 5HT2A receptor agonist.[4] It produces a strong head-twitch response in mice, and this effect is known to correlate with psychedelic effects in humans,[5][6] which suggests that 5-Fluoro-αMT would be an active psychedelic in humans, although it is not known to have been tested in humans and could potentially be dangerous due to its strong inhibition of MAO-A.

See also[edit]


  1. ^ Banks, M. L.; Bauer, C. T.; Blough, B. E.; Rothman, R. B.; Partilla, J. S.; Baumann, M. H.; Negus, S. S. (2014). "Abuse-related effects of dual dopamine/serotonin releasers with varying potency to release norepinephrine in male rats and rhesus monkeys". Experimental and Clinical Psychopharmacology 22 (3): 274–84. doi:10.1037/a0036595. PMID 24796848.  edit
  2. ^ Kinemuchi H, Arai Y. Selective inhibition of monoamine oxidase A and B by two substrate-analogues, 5-fluoro-alpha-methyltryptamine and p-chloro-beta-methylphenethylamine. Research Communications in Chemical Pathology and Pharmacology. 1986 Oct;54(1):125-8.
  3. ^ Kim SK, Toyoshima Y, Arai Y, Kinemuchi H, Tadano T, Oyama K, Satoh N, Kisara K. Inhibition of monoamine oxidase by two substrate-analogues, with different preferences for 5-hydroxytryptamine neurons. Neuropharmacology. 1991 Apr;30(4):329-35.
  4. ^ Chairungsrilerd N, Furukawa K, Tadano T, Kisara K, Ohizumi Y. Effect of gamma-mangostin through the inhibition of 5-hydroxy-tryptamine2A receptors in 5-fluoro-alpha-methyltryptamine-induced head-twitch responses of mice. British Journal of Pharmacology. 1998 Mar;123(5):855-62.
  5. ^ Corne SJ, Pickering RW. A possible correlation between drug induced hallucinations in man and a behavioral response in mice. Psychopharmacologia 1967, 11, 65-78.
  6. ^ Yamamoto T, Ueki S. The role of central serotonergic mechanisms on head-twitch and backward locomotion induced by halluinogenic drugs. Pharmacology, Biochemistry and Behaviour. 1981, 14, 89-95.